Amikacin

A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics. (In Vitro) :Amikacin offers definite advantages for treating infections caused by organisms resistant to other aminoglycosides. Amikaci is affected by relatively few arninoglycoside-modifying enzymes. Amikacin is useful in the treatment of infections caused by Nocardia asteroides, Mycobacterium avium-intracellulare, and certain species of "rapid-growing" mycobacteria (that is, M. chelonae and M. fortuitumi) .Amikacin (100-1500 μM) causes a reliable dose-dependent loss of lateral line zebrafish hair cells with a LD50 value of 453 μM. (In Vivo) :Amikacin (320 mg/kg; subcutaneous injection; daily; for 10 days; male Fischer rats) treatment increases the chance of serious hearing loss in rats in vivo.

Product Specifications

CAS Number

37517-28-5

Product Name Alternative

Antibiotic BB-K 8 | BAY 41-6551 | BB-K 8 | Lukadin | Potentox

Field of Research

Pharmacology & Drug Discovery

Purity

>98% (HPLC)

Solubility

Soluble in Water

Smiles

C1[C@@H] ([C@H] ([C@@H] ([C@H] ([C@@H]1NC (=O) [C@H] (CCN) O) O[C@@H]2[C@@H] ([C@H] ([C@@H] ([C@H] (O2) CO) O) N) O) O) O[C@@H]3[C@@H] ([C@H] ([C@@H] ([C@H] (O3) CN) O) O) O) N